.Attribute Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of people with HER2+ innovative bosom cancer and also energetic or dependable brain metastases revealed steady intracranial activity as well as systemic efficacy of T-DXd.